OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer
Key Points
This study aims to evaluate the effectiveness of DHP107 (oral paclitaxel) compared to intravenous paclitaxel in treating HER2-negative recurrent or metastatic breast cancer.
Conducted as a phase II clinical study
Compared oral DHP107 with intravenous paclitaxel
Targeted patients with HER2-negative breast cancer
Analyzed efficacy and safety outcomes
Preliminary findings indicated potential effectiveness of oral paclitaxel
Safety profiles were comparable between the two treatment options
Patients experienced various responses to both treatments
Abstract
gov no: NCT03326102; date of registration October 19, 2017.